Fulgent Genetics (FLGT) Stock Overview
Provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
FLGT Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Fulgent Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.50 |
| 52 Week High | US$24.64 |
| 52 Week Low | US$14.57 |
| Beta | 0.98 |
| 1 Month Change | 5.57% |
| 3 Month Change | 27.65% |
| 1 Year Change | 22.52% |
| 3 Year Change | -41.37% |
| 5 Year Change | -32.06% |
| Change since IPO | 155.99% |
Recent News & Updates
Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy)
Sep 08Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Is On The Mark
Aug 06
Recent updates
Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy)
Sep 08Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Is On The Mark
Aug 06Here's Why It's Unlikely That Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Will See A Pay Rise This Year
May 09Is Fulgent Genetics (NASDAQ:FLGT) Using Too Much Debt?
May 05
Laboratory, Pathology And Therapeutics Will Expand Future Capabilities
Fulgent Genetics' laboratory services success and sales team's efficiency improvements should drive revenue growth and improve gross margins.Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy
Mar 20Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Jan 15Fulgent Genetics: A Value Stock With Caveats (Rating Downgrade)
Dec 18Fulgent Genetics: An NCAV Pick With Profit And Growth Potential
Sep 25Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst
Sep 09Some Shareholders Feeling Restless Over Fulgent Genetics, Inc.'s (NASDAQ:FLGT) P/S Ratio
Jul 17Fulgent Genetics: Growth Is Returning
Jun 06Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package
May 10Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 07Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?
Mar 01Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Feb 21Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price
Jan 17Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?
Dec 14Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?
Aug 09Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report
May 09Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital
Apr 19Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)
Jan 15Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?
Dec 28What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates
Nov 16Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching
Oct 27Wait For Fulgent Genetics To Grow Up
Oct 13We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending
Sep 19Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly
Sep 05Fulgent Genetics: Poised To Survive Its Post-Covid Hangover
Jul 26Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
Jul 21Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency
Jun 04Fulgent Is Putting Its Cash Bonanza To Work
May 15These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely
May 04Fulgent Genetics: Now The Going Could Get Much Tougher
Apr 10Fulgent Genetics: COVID Bolstered The Underlying Business
Mar 17Shareholder Returns
| FLGT | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 3.3% | 1.0% | -0.1% |
| 1Y | 22.5% | -14.2% | 16.6% |
Return vs Industry: FLGT exceeded the US Healthcare industry which returned -14.2% over the past year.
Return vs Market: FLGT exceeded the US Market which returned 16.7% over the past year.
Price Volatility
| FLGT volatility | |
|---|---|
| FLGT Average Weekly Movement | 5.5% |
| Healthcare Industry Average Movement | 6.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FLGT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FLGT's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,313 | Ming Hsieh | www.fulgentgenetics.com |
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs.
Fulgent Genetics, Inc. Fundamentals Summary
| FLGT fundamental statistics | |
|---|---|
| Market cap | US$733.70m |
| Earnings (TTM) | -US$51.02m |
| Revenue (TTM) | US$303.22m |
Is FLGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLGT income statement (TTM) | |
|---|---|
| Revenue | US$303.22m |
| Cost of Revenue | US$181.82m |
| Gross Profit | US$121.40m |
| Other Expenses | US$172.42m |
| Earnings | -US$51.02m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 07, 2025
| Earnings per share (EPS) | -1.67 |
| Gross Margin | 40.04% |
| Net Profit Margin | -16.83% |
| Debt/Equity Ratio | 0.2% |
How did FLGT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/22 09:00 |
| End of Day Share Price | 2025/10/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fulgent Genetics, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Karen Koski | BTIG |
| Andrew Cooper | CGS International |
| Kevin DeGeeter | Oppenheimer & Co. Inc. |